Reviva Pharmaceuticals Holdi

Reviva Pharmaceuticals Holdings has implemented a 1-for-20 reverse stock split to boost its share price and avoid a Nasdaq delisting, with a critical compliance deadline of March 27. The company also faces financing challenges for an additional Phase 3 trial of its schizophrenia drug candidate, brilaroxazine.

Hims & Hers Health shares surged in premarket trading Monday following reports that Novo Nordisk will resume selling its weight-loss drugs through the telehealth platform. The move marks a reversal from a patent dispute last month.

HKEX shares gained 0.87% to HK$419.00, with a revived IPO pipeline and upcoming policy meetings in Beijing setting the near-term agenda. The exchange reported record 2025 profits of HK$17.8 billion.

Shares of the Tel Aviv Stock Exchange operator jumped 6.4% on Friday, recovering from a prior decline, as trading volumes increased following its schedule change. The market now awaits the Bank of Israel's policy announcement on Monday.

Applied Digital shares surged 25.5% to $34.95 Friday amid heavy trading volume, fueled by renewed investor interest in AI infrastructure stocks. The company's recent hyperscale lease signings and upcoming economic indicators are in focus.

Applied Digital shares surged 25.5% to $34.95 Friday amid heavy trading volume, driven by renewed investor interest in AI-linked infrastructure stocks. The company recently reported $126.6M in quarterly revenue and secured major data center leases.